Loading...
Loading...
SVRA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 21.7M |
| Operating I/L | -22.5M |
| Other Income/Expense | -0.0M |
| Interest Income | 1.4M |
| Pretax | -20.3M |
| Income Tax Expense | -1.3M |
| Net Income/Loss | -20.3M |
Savara Inc. is a clinical stage biopharmaceutical company specializing in rare respiratory diseases. The company's primary focus is on the development of molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, currently in Phase III development for the treatment of autoimmune pulmonary alveolar proteinosis. This product candidate represents the core of Savara's revenue generation strategy, with potential for significant market penetration and revenue generation upon successful regulatory approval and commercialization.
